{
  "guideline": {
    "id": "PA166104948",
    "name": "Annotation of CPIC Guideline for clopidogrel and CYP2C19",
    "source": "CPIC",
    "version": 47,
    "url": "https://www.pharmgkb.org/guidelineAnnotation/PA166104948",
    "relatedChemicals": [
      {
        "id": "PA449053",
        "name": "clopidogrel",
        "symbol": null
      }
    ],
    "relatedGenes": [
      {
        "id": "PA124",
        "name": "cytochrome P450 family 2 subfamily C member 19",
        "symbol": "CYP2C19"
      }
    ],
    "recommendation": true
  },
  "recommendations": [
    {
      "id": "PA166297566",
      "name": "Recommendation PA166297566",
      "population": "CVI ACS PCI",
      "classification": {
        "term": "Strong",
        "termId": "guidelineStrength:981501930"
      },
      "relatedChemicals": [
        {
          "id": "PA449053",
          "name": "clopidogrel",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060168,
        "html": "<p>If considering clopidogrel, use at standard dose (75 mg/day)</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>For cardiovascular indications of acute coronary syndrome (ACS) and/or percutaneous coronary intervention (PCI). ACS and/or PCI includes patients undergoing PCI for an ACS or non-ACS (elective) indication.</p>\n"
      },
      "implications": [
        "CYP2C19: Normal or increased clopidogrel active metabolite formation; normal or lower on-treatment platelet reactivity; no association with higher bleeding risk"
      ],
      "lookupKey": {
        "CYP2C19": "Rapid Metabolizer"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297571",
      "name": "Recommendation PA166297571",
      "population": "CVI ACS PCI",
      "classification": {
        "term": "Strong",
        "termId": "guidelineStrength:981501930"
      },
      "relatedChemicals": [
        {
          "id": "PA449053",
          "name": "clopidogrel",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060173,
        "html": "<p>Avoid clopidogrel if possible. Use prasugrel or ticagrelor at standard dose if no contraindication.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>For cardiovascular indications of acute coronary syndrome (ACS) and/or percutaneous coronary intervention (PCI). ACS and/or PCI includes patients undergoing PCI for an ACS or non-ACS (elective) indication. The strength of recommendation for &quot;likely&quot; phenotypes are the same as their respective confirmed phenotypes. &quot;Likely&quot; indicates the uncertainty in the phenotype assignment, but it is reasonable to apply the recommendation for the confirmed phenotype to the corresponding &quot;likely&quot; phenotype.</p>\n"
      },
      "implications": [
        "CYP2C19: Significantly reduced clopidogrel active metabolite formation; increased on-treatment platelet reactivity; increased risk for adverse cardiac and cerebrovascular events"
      ],
      "lookupKey": {
        "CYP2C19": "Likely Poor Metabolizer"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297584",
      "name": "Recommendation PA166297584",
      "population": "NVI",
      "classification": {
        "term": "No recommendation",
        "termId": "guidelineStrength:1448526251"
      },
      "relatedChemicals": [
        {
          "id": "PA449053",
          "name": "clopidogrel",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060186,
        "html": "<p>No recommendation</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>For neurovascular indications. Neurovascular disease includes acute ischemic stroke or transient ischemic attack, secondary prevention of stroke, or prevention of thromboembolic events following neurointerventional procedures such as carotid artery stenting and stent-assisted coiling of intracranial aneurysms.</p>\n"
      },
      "implications": [
        "CYP2C19: Increased clopidogrel active metabolite formation; lower on-treatment platelet reactivity"
      ],
      "lookupKey": {
        "CYP2C19": "Ultrarapid Metabolizer"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297575",
      "name": "Recommendation PA166297575",
      "population": "CVI non-ACS non-PCI",
      "classification": {
        "term": "No recommendation",
        "termId": "guidelineStrength:1448526251"
      },
      "relatedChemicals": [
        {
          "id": "PA449053",
          "name": "clopidogrel",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060177,
        "html": "<p>No recommendation</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>For non-acute coronary syndrome (non-ACS) and non-percutaneous coronary intervention (non-PCI) cardiovascular indications. Non-ACS, non-PCI cardiovascular indications include peripheral arterial disease and stable coronary artery disease following a recent myocardial infarction outside the setting of PCI.</p>\n"
      },
      "implications": [
        "CYP2C19: Normal or increased clopidogrel active metabolite formation; normal or lower on-treatment platelet reactivity; no association with higher bleeding risk"
      ],
      "lookupKey": {
        "CYP2C19": "Rapid Metabolizer"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297588",
      "name": "Recommendation PA166297588",
      "population": "NVI",
      "classification": {
        "term": "Moderate",
        "termId": "guidelineStrength:981501931"
      },
      "relatedChemicals": [
        {
          "id": "PA449053",
          "name": "clopidogrel",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060190,
        "html": "<p>Consider an alternative P2Y12 inhibitor at standard dose if clinically indicated and no contraindication.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>For neurovascular indications. Neurovascular disease includes acute ischemic stroke or transient ischemic attack, secondary prevention of stroke, or prevention of thromboembolic events following neurointerventional procedures such as carotid artery stenting and stent-assisted coiling of intracranial aneurysms. Alternative P2Y12 inhibitors not impacted by CYP2C19 genetic variants include ticagrelor and ticlopidine. Prasugrel is contraindicated in patients with a history of stroke or TIA. Given limited outcomes data for genotype-guided anti-platelet therapy for neurovascular indications, selection of therapy should depend on individual patient treatment goals and risks for adverse events.</p>\n"
      },
      "implications": [
        "CYP2C19: Reduced clopidogrel active metabolite formation; increased on-treatment platelet reactivity; increased risk for adverse cardiac and cerebrovascular events"
      ],
      "lookupKey": {
        "CYP2C19": "Intermediate Metabolizer"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297567",
      "name": "Recommendation PA166297567",
      "population": "CVI ACS PCI",
      "classification": {
        "term": "Strong",
        "termId": "guidelineStrength:981501930"
      },
      "relatedChemicals": [
        {
          "id": "PA449053",
          "name": "clopidogrel",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060169,
        "html": "<p>If considering clopidogrel, use at standard dose (75 mg/day)</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>For cardiovascular indications of acute coronary syndrome (ACS) and/or percutaneous coronary intervention (PCI). ACS and/or PCI includes patients undergoing PCI for an ACS or non-ACS (elective) indication.</p>\n"
      },
      "implications": [
        "CYP2C19: Normal clopidogrel active metabolite formation; normal on-treatment platelet reactivity"
      ],
      "lookupKey": {
        "CYP2C19": "Normal Metabolizer"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297589",
      "name": "Recommendation PA166297589",
      "population": "NVI",
      "classification": {
        "term": "Moderate",
        "termId": "guidelineStrength:981501931"
      },
      "relatedChemicals": [
        {
          "id": "PA449053",
          "name": "clopidogrel",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060191,
        "html": "<p>Avoid clopidogrel if possible. Consider an alternative P2Y12 inhibitor at standard dose if clinically indicated and no contraindication.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>For neurovascular indications. Neurovascular disease includes acute ischemic stroke or transient ischemic attack, secondary prevention of stroke, or prevention of thromboembolic events following neurointerventional procedures such as carotid artery stenting and stent-assisted coiling of intracranial aneurysms. Alternative P2Y12 inhibitors not impacted by CYP2C19 genetic variants include ticagrelor and ticlopidine. Prasugrel is contraindicated in patients with a history of stroke or TIA. Given limited outcomes data for genotype-guided anti-platelet therapy for neurovascular indications, selection of therapy should depend on individual patient treatment goals and risks for adverse events. The strength of recommendation for &quot;likely&quot; phenotypes are the same as their respective confirmed phenotypes. &quot;Likely&quot; indicates the uncertainty in the phenotype assignment, but it is reasonable to apply the recommendation for the confirmed phenotype to the corresponding &quot;likely&quot; phenotype.</p>\n"
      },
      "implications": [
        "CYP2C19: Significantly reduced clopidogrel active metabolite formation; increased on-treatment platelet reactivity; increased risk for adverse cardiac and cerebrovascular events"
      ],
      "lookupKey": {
        "CYP2C19": "Likely Poor Metabolizer"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297572",
      "name": "Recommendation PA166297572",
      "population": "CVI ACS PCI",
      "classification": {
        "term": "Strong",
        "termId": "guidelineStrength:981501930"
      },
      "relatedChemicals": [
        {
          "id": "PA449053",
          "name": "clopidogrel",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060174,
        "html": "<p>Avoid clopidogrel if possible. Use prasugrel or ticagrelor at standard dose if no contraindication.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>For cardiovascular indications of acute coronary syndrome (ACS) and/or percutaneous coronary intervention (PCI). ACS and/or PCI includes patients undergoing PCI for an ACS or non-ACS (elective) indication.</p>\n"
      },
      "implications": [
        "CYP2C19: Significantly reduced clopidogrel active metabolite formation; increased on-treatment platelet reactivity; increased risk for adverse cardiac and cerebrovascular events"
      ],
      "lookupKey": {
        "CYP2C19": "Poor Metabolizer"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297581",
      "name": "Recommendation PA166297581",
      "population": "CVI non-ACS non-PCI",
      "classification": {
        "term": "Moderate",
        "termId": "guidelineStrength:981501931"
      },
      "relatedChemicals": [
        {
          "id": "PA449053",
          "name": "clopidogrel",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060183,
        "html": "<p>Avoid clopidogrel if possible. Use prasugrel or ticagrelor at standard dose if no contraindication.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>For non-acute coronary syndrome (non-ACS) and non-percutaneous coronary intervention (non-PCI) cardiovascular indications. Non-ACS, non-PCI cardiovascular indications include peripheral arterial disease and stable coronary artery disease following a recent myocardial infarction outside the setting of PCI. The strength of recommendation for &quot;likely&quot; phenotypes are the same as their respective confirmed phenotypes. &quot;Likely&quot; indicates the uncertainty in the phenotype assignment, but it is reasonable to apply the recommendation for the confirmed phenotype to the corresponding &quot;likely&quot; phenotype.</p>\n"
      },
      "implications": [
        "CYP2C19: Significantly reduced clopidogrel active metabolite formation; increased on-treatment platelet reactivity; increased risk for adverse cardiac and cerebrovascular events"
      ],
      "lookupKey": {
        "CYP2C19": "Likely Poor Metabolizer"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297576",
      "name": "Recommendation PA166297576",
      "population": "CVI non-ACS non-PCI",
      "classification": {
        "term": "Strong",
        "termId": "guidelineStrength:981501930"
      },
      "relatedChemicals": [
        {
          "id": "PA449053",
          "name": "clopidogrel",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060178,
        "html": "<p>If considering clopidogrel, use at standard dose (75 mg/day)</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>For non-acute coronary syndrome (non-ACS) and non-percutaneous coronary intervention (non-PCI) cardiovascular indications. Non-ACS, non-PCI cardiovascular indications include peripheral arterial disease and stable coronary artery disease following a recent myocardial infarction outside the setting of PCI.</p>\n"
      },
      "implications": [
        "CYP2C19: Normal clopidogrel active metabolite formation; normal on-treatment platelet reactivity"
      ],
      "lookupKey": {
        "CYP2C19": "Normal Metabolizer"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297585",
      "name": "Recommendation PA166297585",
      "population": "NVI",
      "classification": {
        "term": "No recommendation",
        "termId": "guidelineStrength:1448526251"
      },
      "relatedChemicals": [
        {
          "id": "PA449053",
          "name": "clopidogrel",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060187,
        "html": "<p>No recommendation</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>For neurovascular indications. Neurovascular disease includes acute ischemic stroke or transient ischemic attack, secondary prevention of stroke, or prevention of thromboembolic events following neurointerventional procedures such as carotid artery stenting and stent-assisted coiling of intracranial aneurysms.</p>\n"
      },
      "implications": [
        "CYP2C19: Normal or increased clopidogrel active metabolite formation; normal or lower on-treatment platelet reactivity"
      ],
      "lookupKey": {
        "CYP2C19": "Rapid Metabolizer"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297577",
      "name": "Recommendation PA166297577",
      "population": "CVI non-ACS non-PCI",
      "classification": {
        "term": "No recommendation",
        "termId": "guidelineStrength:1448526251"
      },
      "relatedChemicals": [
        {
          "id": "PA449053",
          "name": "clopidogrel",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060179,
        "html": "<p>No recommendation</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>For non-acute coronary syndrome (non-ACS) and non-percutaneous coronary intervention (non-PCI) cardiovascular indications. Non-ACS, non-PCI cardiovascular indications include peripheral arterial disease and stable coronary artery disease following a recent myocardial infarction outside the setting of PCI. The strength of recommendation for &quot;likely&quot; phenotypes are the same as their respective confirmed phenotypes. &quot;Likely&quot; indicates the uncertainty in the phenotype assignment, but it is reasonable to apply the recommendation for the confirmed phenotype to the corresponding &quot;likely&quot; phenotype.</p>\n"
      },
      "implications": [
        "CYP2C19: Reduced clopidogrel active metabolite formation; increased on-treatment platelet reactivity; increased risk for adverse cardiac and cerebrovascular events"
      ],
      "lookupKey": {
        "CYP2C19": "Likely Intermediate Metabolizer"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297590",
      "name": "Recommendation PA166297590",
      "population": "NVI",
      "classification": {
        "term": "Moderate",
        "termId": "guidelineStrength:981501931"
      },
      "relatedChemicals": [
        {
          "id": "PA449053",
          "name": "clopidogrel",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060192,
        "html": "<p>Avoid clopidogrel if possible. Consider an alternative P2Y12 inhibitor at standard dose if clinically indicated and no contraindication.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>For neurovascular indications. Neurovascular disease includes acute ischemic stroke or transient ischemic attack, secondary prevention of stroke, or prevention of thromboembolic events following neurointerventional procedures such as carotid artery stenting and stent-assisted coiling of intracranial aneurysms. Alternative P2Y12 inhibitors not impacted by CYP2C19 genetic variants include ticagrelor and ticlopidine. Prasugrel is contraindicated in patients with a history of stroke or TIA. Given limited outcomes data for genotype-guided anti-platelet therapy for neurovascular indications, selection of therapy should depend on individual patient treatment goals and risks for adverse events.</p>\n"
      },
      "implications": [
        "CYP2C19: Significantly reduced clopidogrel active metabolite formation; increased on-treatment platelet reactivity; increased risk for adverse cardiac and cerebrovascular events"
      ],
      "lookupKey": {
        "CYP2C19": "Poor Metabolizer"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297582",
      "name": "Recommendation PA166297582",
      "population": "CVI non-ACS non-PCI",
      "classification": {
        "term": "Moderate",
        "termId": "guidelineStrength:981501931"
      },
      "relatedChemicals": [
        {
          "id": "PA449053",
          "name": "clopidogrel",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060184,
        "html": "<p>Avoid clopidogrel if possible. Use prasugrel or ticagrelor at standard dose if no contraindication.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>For non-acute coronary syndrome (non-ACS) and non-percutaneous coronary intervention (non-PCI) cardiovascular indications. Non-ACS, non-PCI cardiovascular indications include peripheral arterial disease and stable coronary artery disease following a recent myocardial infarction outside the setting of PCI.</p>\n"
      },
      "implications": [
        "CYP2C19: Significantly reduced clopidogrel active metabolite formation; increased on-treatment platelet reactivity; increased risk for adverse cardiac and cerebrovascular events"
      ],
      "lookupKey": {
        "CYP2C19": "Poor Metabolizer"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297573",
      "name": "Recommendation PA166297573",
      "population": "CVI ACS PCI",
      "classification": {
        "term": "No recommendation",
        "termId": "guidelineStrength:1448526251"
      },
      "relatedChemicals": [
        {
          "id": "PA449053",
          "name": "clopidogrel",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060175,
        "html": "<p>No recommendation</p>\n"
      },
      "implications": [
        "CYP2C19: n/a"
      ],
      "lookupKey": {
        "CYP2C19": "Indeterminate"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297586",
      "name": "Recommendation PA166297586",
      "population": "NVI",
      "classification": {
        "term": "Strong",
        "termId": "guidelineStrength:981501930"
      },
      "relatedChemicals": [
        {
          "id": "PA449053",
          "name": "clopidogrel",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060188,
        "html": "<p>If considering clopidogrel, use at standard dose (75 mg/day)</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>For neurovascular indications. Neurovascular disease includes acute ischemic stroke or transient ischemic attack, secondary prevention of stroke, or prevention of thromboembolic events following neurointerventional procedures such as carotid artery stenting and stent-assisted coiling of intracranial aneurysms.</p>\n"
      },
      "implications": [
        "CYP2C19: Normal clopidogrel active metabolite formation; normal on-treatment platelet reactivity"
      ],
      "lookupKey": {
        "CYP2C19": "Normal Metabolizer"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297569",
      "name": "Recommendation PA166297569",
      "population": "CVI ACS PCI",
      "classification": {
        "term": "Strong",
        "termId": "guidelineStrength:981501930"
      },
      "relatedChemicals": [
        {
          "id": "PA449053",
          "name": "clopidogrel",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060171,
        "html": "<p>Avoid standard dose clopidogrel (75 mg) if possible. Use prasugrel or ticagrelor at standard dose if no contraindication.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>For cardiovascular indications of acute coronary syndrome (ACS) and/or percutaneous coronary intervention (PCI). ACS and/or PCI includes patients undergoing PCI for an ACS or non-ACS (elective) indication. The strength of recommendation for &quot;likely&quot; phenotypes are the same as their respective confirmed phenotypes. &quot;Likely&quot; indicates the uncertainty in the phenotype assignment, but it is reasonable to apply the recommendation for the confirmed phenotype to the corresponding &quot;likely&quot; phenotype.</p>\n"
      },
      "implications": [
        "CYP2C19: Reduced clopidogrel active metabolite formation; increased on-treatment platelet reactivity; increased risk for adverse cardiac and cerebrovascular events"
      ],
      "lookupKey": {
        "CYP2C19": "Likely Intermediate Metabolizer"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297565",
      "name": "Recommendation PA166297565",
      "population": "CVI ACS PCI",
      "classification": {
        "term": "Strong",
        "termId": "guidelineStrength:981501930"
      },
      "relatedChemicals": [
        {
          "id": "PA449053",
          "name": "clopidogrel",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060167,
        "html": "<p>If considering clopidogrel, use at standard dose (75 mg/day)</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>For cardiovascular indications of acute coronary syndrome (ACS) and/or percutaneous coronary intervention (PCI). ACS and/or PCI includes patients undergoing PCI for an ACS or non-ACS (elective) indication.</p>\n"
      },
      "implications": [
        "CYP2C19: Increased clopidogrel active metabolite formation; lower on-treatment platelet reactivity; no association with higher bleeding risk"
      ],
      "lookupKey": {
        "CYP2C19": "Ultrarapid Metabolizer"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297578",
      "name": "Recommendation PA166297578",
      "population": "CVI non-ACS non-PCI",
      "classification": {
        "term": "No recommendation",
        "termId": "guidelineStrength:1448526251"
      },
      "relatedChemicals": [
        {
          "id": "PA449053",
          "name": "clopidogrel",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060180,
        "html": "<p>No recommendation</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>For non-acute coronary syndrome (non-ACS) and non-percutaneous coronary intervention (non-PCI) cardiovascular indications. Non-ACS, non-PCI cardiovascular indications include peripheral arterial disease and stable coronary artery disease following a recent myocardial infarction outside the setting of PCI.</p>\n"
      },
      "implications": [
        "CYP2C19: Reduced clopidogrel active metabolite formation; increased on-treatment platelet reactivity; increased risk for adverse cardiac and cerebrovascular events"
      ],
      "lookupKey": {
        "CYP2C19": "Intermediate Metabolizer"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297591",
      "name": "Recommendation PA166297591",
      "population": "NVI",
      "classification": {
        "term": "No recommendation",
        "termId": "guidelineStrength:1448526251"
      },
      "relatedChemicals": [
        {
          "id": "PA449053",
          "name": "clopidogrel",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060193,
        "html": "<p>No recommendation</p>\n"
      },
      "implications": [
        "CYP2C19: n/a"
      ],
      "lookupKey": {
        "CYP2C19": "Indeterminate"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297583",
      "name": "Recommendation PA166297583",
      "population": "CVI non-ACS non-PCI",
      "classification": {
        "term": "No recommendation",
        "termId": "guidelineStrength:1448526251"
      },
      "relatedChemicals": [
        {
          "id": "PA449053",
          "name": "clopidogrel",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060185,
        "html": "<p>No recommendation</p>\n"
      },
      "implications": [
        "CYP2C19: n/a"
      ],
      "lookupKey": {
        "CYP2C19": "Indeterminate"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297570",
      "name": "Recommendation PA166297570",
      "population": "CVI ACS PCI",
      "classification": {
        "term": "Strong",
        "termId": "guidelineStrength:981501930"
      },
      "relatedChemicals": [
        {
          "id": "PA449053",
          "name": "clopidogrel",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060172,
        "html": "<p>Avoid standard dose (75 mg) clopidogrel if possible. Use prasugrel or ticagrelor at standard dose if no contraindication.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>For cardiovascular indications of acute coronary syndrome (ACS) and/or percutaneous coronary intervention (PCI). ACS and/or PCI includes patients undergoing PCI for an ACS or non-ACS (elective) indication.</p>\n"
      },
      "implications": [
        "CYP2C19: Reduced clopidogrel active metabolite formation; increased on-treatment platelet reactivity; increased risk for adverse cardiac and cerebrovascular events"
      ],
      "lookupKey": {
        "CYP2C19": "Intermediate Metabolizer"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297587",
      "name": "Recommendation PA166297587",
      "population": "NVI",
      "classification": {
        "term": "Moderate",
        "termId": "guidelineStrength:981501931"
      },
      "relatedChemicals": [
        {
          "id": "PA449053",
          "name": "clopidogrel",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060189,
        "html": "<p>Consider an alternative P2Y12 inhibitor at standard dose if clinically indicated and no contraindication.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>For neurovascular indications. Neurovascular disease includes acute ischemic stroke or transient ischemic attack, secondary prevention of stroke, or prevention of thromboembolic events following neurointerventional procedures such as carotid artery stenting and stent-assisted coiling of intracranial aneurysms. Alternative P2Y12 inhibitors not impacted by CYP2C19 genetic variants include ticagrelor and ticlopidine. Prasugrel is contraindicated in patients with a history of stroke or TIA. Given limited outcomes data for genotype-guided anti-platelet therapy for neurovascular indications, selection of therapy should depend on individual patient treatment goals and risks for adverse events. The strength of recommendation for &quot;likely&quot; phenotypes are the same as their respective confirmed phenotypes. &quot;Likely&quot; indicates the uncertainty in the phenotype assignment, but it is reasonable to apply the recommendation for the confirmed phenotype to the corresponding &quot;likely&quot; phenotype.</p>\n"
      },
      "implications": [
        "CYP2C19: Reduced clopidogrel active metabolite formation; increased on-treatment platelet reactivity; increased risk for adverse cardiac and cerebrovascular events"
      ],
      "lookupKey": {
        "CYP2C19": "Likely Intermediate Metabolizer"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297574",
      "name": "Recommendation PA166297574",
      "population": "CVI non-ACS non-PCI",
      "classification": {
        "term": "No recommendation",
        "termId": "guidelineStrength:1448526251"
      },
      "relatedChemicals": [
        {
          "id": "PA449053",
          "name": "clopidogrel",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060176,
        "html": "<p>No recommendation</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>For non-acute coronary syndrome (non-ACS) and non-percutaneous coronary intervention (non-PCI) cardiovascular indications. Non-ACS, non-PCI cardiovascular indications include peripheral arterial disease and stable coronary artery disease following a recent myocardial infarction outside the setting of PCI.</p>\n"
      },
      "implications": [
        "CYP2C19: Increased clopidogrel active metabolite formation; lower on-treatment platelet reactivity; no association with higher bleeding risk"
      ],
      "lookupKey": {
        "CYP2C19": "Ultrarapid Metabolizer"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    }
  ],
  "citations": [
    {
      "pmid": "35034351",
      "title": "Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2C19 Genotype and Clopidogrel Therapy: 2022 Update.",
      "authors": [
        "Lee Craig R",
        "Luzum Jasmine A",
        "Sangkuhl Katrin",
        "Gammal Roseann S",
        "Sabatine Marc S",
        "Stein Charles Michael",
        "Kisor David F",
        "Limdi Nita A",
        "Lee Yee Ming",
        "Scott Stuart A",
        "Hulot Jean-Sébastien",
        "Roden Dan M",
        "Gaedigk Andrea",
        "Caudle Kelly E",
        "Klein Teri E",
        "Johnson Julie A",
        "Shuldiner Alan R"
      ],
      "journal": "Clinical pharmacology and therapeutics",
      "year": 2022,
      "_sameAs": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9287492"
    },
    {
      "pmid": "23698643",
      "title": "Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update.",
      "authors": [
        "Scott S A",
        "Sangkuhl K",
        "Stein C M",
        "Hulot J-S",
        "Mega J L",
        "Roden D M",
        "Klein T E",
        "Sabatine M S",
        "Johnson J A",
        "Shuldiner A R",
        "Clinical Pharmacogenetics Implementation Consortium"
      ],
      "journal": "Clinical pharmacology and therapeutics",
      "year": 2013,
      "_sameAs": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3748366"
    },
    {
      "pmid": "21716271",
      "title": "Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy.",
      "authors": [
        "Scott S A",
        "Sangkuhl K",
        "Gardner E E",
        "Stein C M",
        "Hulot J-S",
        "Johnson J A",
        "Roden D M",
        "Klein T E",
        "Shuldiner A R",
        "Clinical Pharmacogenetics Implementation Consortium"
      ],
      "journal": "Clinical pharmacology and therapeutics",
      "year": 2011,
      "_sameAs": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3234301"
    }
  ],
  "version": "2024-02-29-20-19"
}